GlassScriptPhysician profile
Steven B Inbody
NPI 1699701417
$248.14
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $43.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $61.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.95 | 2019 | |
| Grifols USA, LLC | $48.66 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.88 | 2020 | |
| Assertio Therapeutics, INC. | $20.79 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.66 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Inbody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.